A Scientific Statement From the AHA on CV Risk in Nonalcoholic Fatty Liver Disease
The American Heart Association has issued a scientific statement regarding the relationship between nonalcoholic fatty liver disease and cardiovascular risk.
The American Heart Association has issued a scientific statement regarding the relationship between nonalcoholic fatty liver disease and cardiovascular risk.
A study was conducted to determine if icosapent ethyl is effected by patient baseline abdominal obesity.
Researchers assessed potential discordance among the Friedewald, Sampson, and Martin/Hopkins equations used for estimating LDL-cholesterol.
Researchers investigated the efficacy of a new drug containing a naturally derived krill oil mixture for treatment of severe hypertriglyceridemia.
Patients with type 2 diabetes still have a high risk for cardiovascular disease—even after lowering LDL cholesterol.
“We are extremely disappointed with the FDA’s decision. We continue to feel strongly that Waylivra demonstrates a favorable benefit/risk profile in people with FCS,” said Akcea CEO, Paula Soteropoulos.
Patients with familial chylomicronemia syndrome who were actively connected were also 3 times as likely to report “high” or “extremely high” motivation in managing their own health.
Antisense technology refers to the use of synthetic nucleic acid sequences to interrupt specific protein production by targeting the corresponding messenger RNA that encodes that protein.